Symbiotec Pharma Lab is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. With over 30 years of industry experience, it has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform.

The company has a strong position in corticosteroid and steroidal-hormone APIs, which are key ingredients used in medicines for conditions such as inflammation, allergies, asthma and hormonal disorders. In FY26, it held a 38.2% global volume market share in corticosteroid APIs and 23.8% in steroidal-hormone APIs, excluding androstenedione and hydroxyprogesterone caproate. It is also the only Indian and global company with a presence across the top 10 corticosteroid and steroidal-hormone APIs in FY26.

As of March 31, 2026, the company operated through three complementary verticals API products, CDMO services and complex injectables and had supplied products to over 200 customers across more than 40 countries, including leading generic and specialty pharmaceutical companies in the US, Europe and Asia.

In FY26, Revenue from APIs contributed 96.07% to overall revenue, CDMO 0.13%, and complex injectables 3.8%.

In FY26, the company derived 67.04% of its revenue from international markets and 32.96% from domestic markets.

Its portfolio comprises over 60 APIs, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are supplied for critical care and chronic therapies across respiratory, dermatology, pain management, oncology and gynaecology. The company holds a global leadership position in Hydrocortisone, Testosterone and Methylprednisolone, with volume market shares of 80.1%, 76.4% and 76.0%, respectively, in FY26.

Its capabilities span three interconnected platforms: (1) organic chemistry, including flow chemistry, hydrogenation and photochemistry. (2) Biotechnology, including biosynthesis, biotransformation and recombinant biologics such as GLP-1 and insulin; and (3) complex injectables, including double-chamber vials, bags and syringes. The company uses fermentation and complex, multi-step chemical reactions in its manufacturing processes. This combination enables it to develop, manufacture and scale complex and difficult-to-replicate pharmaceutical products, while expanding into higher-value segments.

In CDMO segment, it offers products and services across the same three platforms in which it manufactures its own products, allowing it to leverage its existing capabilities and manufacturing infrastructure across both its own products and CDMO engagements.

The company has secured long-term CDMO arrangements, including five-year and ten-year take-or-pay contracts for insulin drug substance and classical fermentation-based APIs, respectively, along with a 10-year take-or-pay contract for an alternative protein product with a US company. It also plans to deepen relationships with existing clients and pursue new opportunities across the US, Europe and other international markets.

The company has approvals and regulatory credentials across key global markets, including US FDA, EU-GMP and Korea’s Ministry of Food and Drug Safety. As of March 31, 2026, it had 43 Drug Master Files (DMFs) registered with the US FDA and 23 Certificates of Suitability (CEPs) from the EDQM, supporting its ability to supply APIs to highly regulated international markets.

The company follows a “farm/microbe-to-pharmacy” approach by converting plant-based inputs and using microbial strains such as bacteria, fungi, yeast and algae to produce high-value steroid and hormone precursors. This provides backward integration and enables it to make key starting materials (KSMs) in-house for over 80% of its products by revenue, reducing dependence on external suppliers and intermediates sourced from other geographies.

Plans to collaborate with pharmaceutical companies on complex, high-barrier projects through collaborations involving milestone payments, royalties and profit sharing. For instance, it has entered into a collaboration with a global specialty pharmaceutical company for conjugated estrogen products, which are widely used in hormone replacement therapy (HRT) to manage menopausal symptoms and prevent osteoporosis. The agreement includes milestone payments and profit-sharing arrangements.

As of March 31, 2026, the company had two operational industrial-scale API manufacturing facilities with maximum chemical synthesis capacity of 584.67 MT and fermentation capacity of 300 KL. It has also commissioned two additional facilities at Ujjain and Mhow, Madhya Pradesh, taking aggregate fermentation capacity to 700 KL and adding complex injectable capacity of 20 million double-chamber vials (DCVs) per annum. Its biotechnology facilities are equipped with 5 KL, 35 KL and 100 KL fermenters, providing flexibility across different production scales.

Further, the company is expanding its biologics capacity by adding a proposed 14 KL fermentation facility at Ujjain, comprising two 7 KL reactors, to cater to growing demand for GLP-1 and insulin.

The company has invested over Rs 798.61 crore over the last three financial years to expand its API and complex injectable manufacturing capacities and capabilities. To strengthen its CDMO business, it has also signed multiple contracts to develop and supply complex biotechnology products to specialty pharmaceutical, food and nutraceutical companies globally.

The company operates three dedicated R&D centres in Indore focused on organic chemistry, biotechnology and complex injectables. It invested 3.42% of revenue in R&D in FY26.

Plans to strengthen its position in corticosteroid and steroidal-hormone APIs by expanding into new product categories, therapeutic areas and global markets. It is also expanding into classical fermentation-based APIs, niche high-value, low-volume APIs and specialty ingredients such as Vegan Vitamin D3 and algal-based DHA.

Plans to commercialize its first two double-chamber vial products, Methylprednisolone Sodium Succinate and Hydrocortisone Sodium Succinate, in FY27 and is developing additional products under the 505(b)(2) pathway.

Offer and its objects

The IPO comprises fresh issue of equity shares worth up to Rs 150 crore and an offer for sale aggregating up to Rs 1,607 crore by Satwani Holdings LLP, Rosewood Investments, and India Business Excellence Fund – III.

Price band for the IPO is Rs 938 to Rs 988 per equity share of face value Rs 2 each.

The objectives for the fresh issue includes Rs 112.5 crore for Prepayment/repayment of certain outstanding borrowings, and remaining amount for general corporate purpose.

The promoters are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP. The promoters and promoter group hold an aggregate of 2,28,41,312 equity shares, aggregating to 36.41% of the pre-offer issued and paid-up equity share capital. Their post IPO shareholding is expected to be around 33.28%.

The issue, through the book-building process, will open on 24 Aug 2026 and will close on 27 Aug 2026.

Strengths

Its “farm/microbe-to-pharmacy” approach enables in-house production of KSMs for over 80% of products by revenue, reducing dependence on external suppliers and improving supply control.

Long-standing relationships with a diverse global customer base, serving over 200 customers across 40+ countries, including leading generic and specialty pharmaceutical companies.

Leader in corticosteroid and steroidal-hormone APIs, with 38.2% and 23.8% global volume market share, respectively, in FY26. It also leads in Hydrocortisone, Testosterone and Methylprednisolone, with volume market shares of 80.1%, 76.4% and 76.0%, respectively, in FY26.

The complex nature of its APIs and stringent regulatory requirements create high switching costs, supporting customer retention.

Strong regulatory compliance track record, with over 108 customer inspections and nine regulatory inspections by agencies including the US FDA, EU-GMP, ANVISA and PMDA over the last three financial years, with no critical observations.

Strong R&D and technology capabilities enable it to manufacture complex and difficult-to-replicate products.

Rising demand for fermentation-based products, supported by the China+1 sourcing trend, is expected to help the company expand its biologics platform and enter new therapeutic categories.

Extensive experience of promoters and senior management personnel.

Weaknesses

High dependence on the API business, contributing 96.07% to FY26 revenue.

Exposed to forex fluctuations, geopolitical uncertainties, trade restrictions and changes in regulatory requirements across markets. In FY26, exports contributed 67.04% to revenue, while the US accounted for 13.12%, creating additional exposure to potential tariffs and anti-outsourcing measures.

Operations are subject to extensive regulatory, environmental, health, safety and labour requirements, with non-compliance potentially resulting in sanctions, shutdowns, approval delays and higher compliance costs.

Dependence on imports from China, which accounted for 23.88% of raw material expenses in FY26, exposing the company to potential supply-chain disruptions, geopolitical tensions, tariffs and regulatory changes.

Expansion across APIs, biotechnology, CDMO and complex injectables requires significant capital investment and may affect returns if utilization ramps up slowly.

There are outstanding litigation proceedings (including criminal) involving Company, Promoters, Directors. Any adverse outcome in such proceedings may have an adverse impact on its reputation and business.

Promoters and certain promoter-group members had pledged 13.22% of pre-Offer equity share capital. Although the pledge has been released, it may be re-pledged, and any enforcement could dilute promoter shareholding and affect control.

The relatively new CDMO business depends on a limited number of customers, while scaling new projects and securing long-term contracts may involve lengthy development, validation and regulatory timelines.

Valuation

Net sales increased 16% to Rs 869.15 crore in FY26 as compared with FY25. The OPM improved 51 bps to 27.37%, leading to 18% increase in OP to Rs 237.86 crore. OI fell 30% to Rs 3.11 crore. Interest cost rose 58% to Rs 25.33 crore. Depreciation cost went up 24% to Rs 53.28 crore. PBT increased 10% to Rs 162.35 crore. Exceptional items stood at Rs 8.99 crore compared to nil. Tax expenses were Rs 43.46 crore as compared with Rs 50.19 crore. Net profit increased 14% to Rs 109.88 crore.

The FY26 EPS (excluding extraordinary items and relevant tax) on post-issue equity works out to Rs 18.1. At the upper price band of Rs 988, P/E is 55.

Total outstanding borrowings amounted to Rs 349.78 crore as on March 31, 2026. As much as 32% of the debt will be repaid from the issue proceeds, bringing down interest costs substantially and boosting profit. The FY26 EPS works out to Rs 19 if 32% of its interest cost is removed, keeping all other items, including tax rate, same. The re-worked P/E at the upper price band moderates to 52.

Listed peers such as Concord Biotech traded at FY26 P/E of 62, Divi‘s Laboratories at FY26 P/E of 87, Cohance Lifesciences at FY26 P/E of 86, and Laurus Labs at FY26 P/E of 109 as on 22 Aug 2026. The OPM and ROE stood at 27.37% and 11.19% respectively, in FY26. These were 34.84% and 14% for Concord Biotech, 32.59% and 16.5% for Divi‘s Laboratories, 18.82% and 7% for Cohance Lifesciences, and 26.09% and 17% for Laurus Labs, respectively.